Table 4.
Joint/Combined Associations of Selected Genotypes and BMI with Risk of Pancreatic Cancer
| Genotype | BMI (kg/m2) |
Case/Control (n/n) |
AOR (95% CI)a | LRT |
|---|---|---|---|---|
| PPARG Ex4−49C>G | ||||
| CC | <25 | 361/368 | 1.00 | |
| CG/GG | <25 | 91/109 | 0.98 (0.71–1.36) | |
| CC | ≥25 | 344/238 | 1.63 (1.27–2.09) | |
| CG/GG | ≥25 | 96/74 | 1.50 (1.04–2.16) | 0.80 |
| PRKAA2 Ex9+2011A>C | ||||
| AA | <25 | 118/132 | 1.00 | |
| AC/CC | <25 | 333/346 | 1.13 (0.84–1.53) | |
| AA | ≥25 | 131/108 | 1.38 (0.94–2.03) | |
| AC/CC | ≥25 | 313/207 | 1.98 (1.42–2.76) | 0.30 |
| PRKAB2 Ex7−247T>G | ||||
| TT/ GT | <25 | 412/419 | 1.00 | |
| GG | <25 | 40/56 | 0.75 (0.48–1.17) | |
| TT/ GT | ≥25 | 398/277 | 1.58 (1.25–1.99) | |
| GG | ≥25 | 45/38 | 1.17 (0.72–1.91) | 0.97 |
| PRKAB1 −309C>A | ||||
| CC/ AC | <25 | 419/434 | 1.00 | |
| AA | <25 | 37/45 | 0.86 (0.53–1.38) | |
| CC/ AC | ≥25 | 401/279 | 1.63 (1.29–2.05) | |
| AA | ≥25 | 44/38 | 1.15 (0.70–1.88) | 0.58 |
| PRKAB2 Ex8+1306G>A | ||||
| GG | <25 | 180/190 | 1.00 | |
| AG/AA | <25 | 269/282 | 0.92 (0.70–1.21) | |
| GG | ≥25 | 154/107 | 1.60 (1.14–2.25) | |
| AG/AA | ≥25 | 285/206 | 1.44 (1.07–1.94) | 0.94 |
| NR5A2 −91147C>T | ||||
| CC | <25 | 167/168 | 1.00 | |
| CT/TT | <25 | 282/309 | 0.88 (0.67–1.17) | |
| CC | ≥25 | 170/94 | 1.83 (1.28–2.61) | |
| CT/TT | ≥25 | 275/222 | 1.33 (0.99–1.80) | 0.38 |
| NR5A2 IVS2+1901C>T | ||||
| CT/TT | <25 | 230/222 | 1.00 | |
| CC | <25 | 214/254 | 0.75 (0.57–0.99) | |
| CT/TT | ≥25 | 235/143 | 1.64 (1.21–2.22) | |
| CC | ≥25 | 206/171 | 1.20 (0.89–1.62) | 0.89 |
| NR5A2 IVS1−1354A>G | ||||
| AG/GG | <25 | 284/280 | 1.00 | |
| AA | <25 | 168/199 | 0.76 (0.58–1.01) | |
| AG/GG | ≥25 | 284/170 | 1.74 (1.32–2.30) | |
| AA | ≥25 | 157/142 | 1.13 (0.83–1.53) | 0.42 |
| ADIPOQ Ex3+117T>C | ||||
| TT | <25 | 427/431 | 1.00 | |
| CT/CC | <25 | 22/48 | 0.45 (0.26–0.77) | |
| TT | ≥25 | 411/295 | 1.52 (1.21–1.90) | |
| CT/CC | ≥25 | 30/19 | 1.67 (0.89–3.14) | 0.03 |
| ADIPOQ IVS1+244G>A | ||||
| GG/AG | <25 | 396/429 | 1.00 | |
| AA | <25 | 54/47 | 1.14 (0.74–1.76) | |
| GG/AG | ≥25 | 387/273 | 1.61 (1.27–2.03) | |
| AA | ≥25 | 53/38 | 1.80 (1.13–2.88) | 0.97 |
| ADIPOQ Ex2+53T>G | ||||
| TT | <25 | 358/367 | 1.00 | |
| GT/GG | <25 | 91/107 | 0.85 (0.61–1.18) | |
| TT | ≥25 | 343/241 | 1.56 (1.22–2.00) | |
| GT/GG | ≥25 | 96/68 | 1.53 (1.06–2.21) | 0.57 |
| ADIPOQ IVS1−4514C>T | ||||
| CC | <25 | 237/255 | 1.00 | |
| CT/TT | <25 | 208/218 | 1.02 (0.78–1.34) | |
| CC | ≥25 | 239/169 | 1.57 (1.18–2.10) | |
| CT/TT | ≥25 | 197/141 | 1.65 (1.21–2.25) | 0.89 |
| FTO IVS1−40478T>A | ||||
| TT | <25 | 171/169 | 1.00 | |
| AT/AA | <25 | 286/313 | 0.86 (0.65–1.14) | |
| TT | ≥25 | 158/114 | 1.29 (0.91–1.83) | |
| AT/AA | ≥25 | 287/204 | 1.53 (1.13–2.08) | 0.14 |
| FTO IVS1−27777C>A | ||||
| CC | <25 | 181/163 | 1.00 | |
| AC/AA | <25 | 273/313 | 0.72 (0.55–0.96) | |
| CC | ≥25 | 138/128 | 0.93 (0.66–1.33) | |
| AC/AA | ≥25 | 304/185 | 1.54 (1.14–2.09) | 0.0001 |
| FTO IVS1−23525T>A | ||||
| TT | <25 | 183/170 | 1.00 | |
| AT/AA | <25 | 270/307 | 0.78 (0.59–1.03) | |
| TT | ≥25 | 144/128 | 1.04 (0.73–1.47) | |
| AT/AA | ≥25 | 296/183 | 1.60 (1.18–2.17) | 0.0015 |
AOR: adjusted odds ratio; 95% CI: 95% confidence interval; BMI: body mass index; LRT: likelihood ratio test.
a
OR was adjusted for sex, age (continuous), race, education, smoking, alcohol, history of diabetes, and family history of cancer.